Irbesartán/Hidroclorotiazida Stada (Hydrochlorothiazide, Irbesartan)

Irbesartan blocks AT1 receptors, preventing angiotensin II from causing vasoconstriction and aldosterone release. This leads to relaxation of blood vessels and reduced fluid retention, contributing to lower blood pressure.

The appropriate dose is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and any concomitant medications. Dosage adjustments are made according to clinical judgment.

Safety in pregnancy has not been established, and the drug should be avoided unless the potential benefit justifies the risk. Limited data are available for breastfeeding; a healthcare professional should evaluate the risk‑benefit ratio.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and import documentation.

Compared with monotherapy, the Irbesartan/Hydrochlorothiazide combo offers dual mechanisms—vascular relaxation and diuresis—providing more potent blood‑pressure control. It may reduce pill burden versus separate agents, but individual patient factors determine the optimal regimen.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and keep out of reach of children.

The medication is taken orally, usually once daily, with or without food, as directed by a healthcare professional. Swallow the tablet whole with a glass of water; do not crush or chew unless instructed otherwise.

Serious adverse events include severe hypotension, acute kidney injury, hyperkalemia, angioedema, and rare cases of pancreatitis. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden weakness, or marked changes in urine output.

Individuals with known hypersensitivity to irbesartan, hydrochlorothiazide, or any component of the formulation should avoid this medication. It is also contraindicated in patients with severe renal impairment, hyperkalemia, or those taking potassium‑sparing agents without close monitoring.